Skip to content
The Chat Archive
gpt-4o-2024-08-06· OpenAI WildChat-4.8M (AI2)

System: Create a comprehensive dataset for financial entity recognition. Label all…

  1. User

    System: Create a comprehensive dataset for financial entity recognition. Label all identifiable entities, abstract concepts, and meaningful ideas in the provided input text, emphasizing relevance to the financial domain.

    Ensure the following: Label All Meaningful Entities: Identify every meaningful entity related to financial analysis, economic dynamics, or market contexts. Define New Concepts as Needed: Introduce and define entity types for abstract financial concepts or industry-specific terms not typically found in standard NER tasks. Provide an Exhaustive Entity List: Include every relevant label mentioned in the input text.

    Respond in the following format: | | <description of entity group/concept>, | | <description of entity group/concept>, ... Input: User: Bristol Myers Squibb (BMY) and 2seventy bio, Inc.'s efforts to seek approval for the label expansion of Abecma for earlier lines of treatment face a roadblock. Assistant:

  2. Assistant

    Bristol Myers Squibb | Company | A global biopharmaceutical company involved in the development, manufacturing, and commercialization of pharmaceutical products, BMY | Stock Ticker | The stock ticker symbol for Bristol Myers Squibb, used in financial markets to represent the company's publicly traded shares, 2seventy bio, Inc. | Company | A biotechnology company specializing in innovative cell therapies for cancer, Abecma | Product | A CAR-T cell therapy product developed for the treatment of multiple myeloma, label expansion | Regulatory Process | The process of updating a drug's label to include new information, such as additional approved uses or therapies, earlier lines of treatment | Treatment Strategy | Refers to the use of a therapy in the initial stages or early phases of a treatment plan for a condition, approval | Regulatory Process | The official consent by a governmental regulatory agency, such as the FDA, for a drug or treatment to be marketed and used for specific indications or populations, roadblock | Obstacle | Challenges or barriers that hinder or delay the progress in a process, such as regulatory approval.